Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186355 · ClinicalTrials.gov registry record · NA
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
NCT00186355: Completed NA study, sponsored by Stanford University.
NCT00186355 is a NA study that has completed, run by Stanford University. The registered enrollment target is 97 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186355, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
Study Summary
To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.
Interventions
- PROCEDURE high dose chemo then auto hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2003-10 |
| Est. Completion | 2010-02 |
| Phase | NA |
What the finished NCT00186355 record still lists
NCT00186355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which high dose chemo then auto hematopoietic cell transplant is the first listed.
NCT00186355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186355 about?
NCT00186355 is a clinical study titled "Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma". To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.
What is the current status of trial NCT00186355?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2003-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00186355?
The interventions under investigation include: high dose chemo then auto hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186355?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186355's enrollment target sits among peer trials
97 923rd of 2000 higher than 1,076 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia